14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ACCL vs SBC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, SBC Medical Group Holdings Incorporated (SBC) is the stronger overall head-to-head candidate over ACCL (ACCL) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACCL carries a Unified Composite Score of 63.4/100 (BUY) at $2.36 (N/M Forward P/E, 4.5% operating margin), whereas SBC carries 47.6/100 (HOLD) at $6.42 (13.6x Forward P/E, 37.3% operating margin).
Composite vs. Pillar Nuance: While ACCL currently prints a higher short-term Unified Composite Score (63.4/100 BUY vs. SBC 47.6/100 HOLD), SBC captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (37.3% vs. 4.5% operating margin) and revenue trajectory (+13.4% vs. +11.3% YoY).
Technical & Structure Timing Caution: ACCL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2); meanwhile SBC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACCL vs SBC. Trailing 12-month operating profitability (ACCL 4.5% vs SBC 37.3%) and valuation multiples (ACCL N/M vs SBC 13.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Consulting Services value chain with $33.5M market capitalization and 4.5% operating margin.
OpEx & R&D Reinvestment37.9% of Rev ($2.0M)
90D Engineering Disclosures0 Published
SBC Moat ProfileHigh-Margin Pricing Power Moat
Consulting Services Operator
Competes within the Consulting Services value chain with $549.2M market capitalization and 37.3% operating margin.
OpEx & R&D Reinvestment34.6% of Rev ($61M)
90D Engineering Disclosures0 Published
Investor FAQ ACCL vs SBC Key Questions & Quantitative Answers
As of Nov 16, 2026, SBC Medical Group Holdings Incorporated (SBC) is the stronger overall head-to-head candidate over ACCL (ACCL) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACCL carries a Unified Composite Score of 63.4/100 (BUY) at $2.36 (N/M Forward P/E, 4.5% operating margin), whereas SBC carries 47.6/100 (HOLD) at $6.42 (13.6x Forward P/E, 37.3% operating margin). Composite vs. Pillar Nuance: While ACCL currently prints a higher short-term Unified Composite Score (63.4/100 BUY vs. SBC 47.6/100 HOLD), SBC captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (37.3% vs. 4.5% operating margin) and revenue trajectory (+13.4% vs. +11.3% YoY). Technical & Structure Timing Caution: ACCL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2); meanwhile SBC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SBC leads the Growth & Scale pillar: ACCL posts +11.3% YoY revenue growth and -62.5% YoY earnings growth on $5.2M TTM revenue (42.4% gross margin, 4.5% operating margin), compared with SBC at +13.4% YoY revenue growth and +338.9% YoY earnings growth on $175M TTM revenue (71.9% gross margin, 37.3% operating margin). On trailing 12-month operating scale, ACCL generates $5.2M in USD-normalized revenue versus $175M for SBC. In operating R&D and SG&A reinvestment, ACCL deploys 37.9% of Rev ($2.0M) (0 90-day corporate R&D disclosures) versus 34.6% of Rev ($61M) (0 disclosures) for SBC.
SBC screens cheaper on headline valuation multiples. ACCL trades at N/M Forward P/E, 120.0x Trailing P/E, N/M PEG, and 6.5x EV/Revenue (4.7% EBITDA margin), whereas SBC trades at 13.6x Forward P/E, 11.4x Trailing P/E, 2.02x PEG, and 3.1x EV/Revenue (39.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACCL (7.0% ROE) versus SBC (18.9% ROE) capital efficiency.
In options market volatility and institutional positioning, ACCL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.20β · 60% Vol realized risk). By comparison, SBC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 150% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.